Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 7/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948709 | 0.95 | F10 (0.38) | ALDH1A1LMNAMEN1HPGDKMT2A | |
| SCHEMBL948425 | 0.80 | F10 (0.39) | ALDH1A1LMNAMEN1HPGDKMT2A | |
| SCHEMBL948341 | 0.76 | F10 (0.63) | F10F2 | |
| Hydrochloric Acid SCHEMBL949834 | 0.75 | F10 (0.62) | F10F2 | |
| Hydrochloric Acid SCHEMBL948714 | 0.75 | NPC1 (0.41) | ALDH1A1LMNAMEN1HPGDKMT2A | |
| SCHEMBL3448784 | 0.75 | EPHX2 (0.46) | LMNAMAPTSMN1; SMN2CNR1 | |
| SCHEMBL949035 | 0.74 | F10 (0.62) | ALDH1A1LMNAMEN1HPGDKMT2A | |
| SCHEMBL949033 | 0.74 | F10 (0.62) | ALDH1A1LMNAMEN1HPGDKMT2A | |
| SCHEMBL949018 | 0.74 | F10 (0.47) | F10F2 | |
| SCHEMBL949173 | 0.74 | F10 (0.39) | F10F2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | ALDH1A1 2246/4885LMNA 2660/4885MEN1 1291/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | ALDH1A1 2316/4885LMNA 2787/4885MEN1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.